Keywords: good, data, novartis, aclasta, vs, risedronate, swiss

Good data for Novartis' Aclasta vs risedronate

Article | 27 March 2006

Print This

Swiss drug major Novartis has reported strong data on Aclasta (zoledronic acid 5mg solution for infusion), as a treatment for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in